SCHEMBL4941587

SCHEMBL4941587

CNS(=O)(=O)c1ccc(-c2ccccc2)c(C(=O)O)c1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.54
CHUK O15111 1/20 0.54
L3MBTL1 Q9Y468 2/20 0.49
FOLH1 Q04609 1/20 0.48
ADAMTS4 O75173 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
KDM4E B2RXH2 1/20 0.46
POLB P06746 1/20 0.46
TNNI3K Q59H18 1/20 0.45
ACLY P53396 3/20 0.43
LMNA P02545 2/20 0.43
GAA P10253 1/20 0.43
NR3C2 P08235 1/20 0.43
PTGS2 P35354 1/20 0.43
ALDH1A1 P00352 2/20 0.43
MCOLN3 Q8TDD5 1/20 0.43
HSD17B10 Q99714 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15606213 0.83 IKBKB (0.55) IKBKBCHUKADAMTS4ACLYGAA
SCHEMBL3875822 0.83 LMNA (0.58) FOLH1LMNAPTGS2HSD17B10
SCHEMBL7084515 0.79 FOLH1 (0.48) FOLH1ADAMTS4LMNAPTGS2HSD17B10
SCHEMBL2825786 0.78 ALDH1A1 (0.62) L3MBTL1MEN1KMT2AKDM4EPOLB
SCHEMBL19119211 0.78 POLB (0.59) L3MBTL1MEN1KMT2AKDM4EPOLB
SCHEMBL4844487 0.76 KMT2A (0.50) IKBKBCHUKL3MBTL1MEN1KMT2A
SCHEMBL29602365 0.76 CYP3A4 (0.52) L3MBTL1MEN1KMT2AKDM4EPOLB
SCHEMBL12225751 0.76 HSD17B10 (0.54) L3MBTL1MEN1KMT2AKDM4EPOLB
SCHEMBL13543494 0.76 CYP3A4 (0.52) L3MBTL1MEN1KMT2AKDM4EPOLB
SCHEMBL30602792 0.76 LMNA (0.45) IKBKBCHUKL3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors GLAXO GROUP LIMITED 2008-10-16 US disclosed
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors GLAXO GROUP LIMITED 2008-10-16 US disclosed
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors GLAXO GROUP LIMITED 2008-10-16 US disclosed
EP-1858869-A1 ACYLATED PIPERIDINES AS GLYCINE TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006094842-A1 ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed
WO-2006094842-A1 ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors SLC1A1, SLC6A7, SLC1A2 IKBKB 4024/4885CHUK 2641/4885L3MBTL1 928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.